Type 2 Diabetes

The US regulator has called for new eye-related warnings on GLP-1 drug labels, but Indian safety data remains limited

Global review covering over 200 million participant observations links prolonged PM2.5 exposure to higher Type 2 diabetes risk, highlighting metabolic health concerns in polluted regions

The approval makes South Africa the second market after India where the drugmaker has secured regulatory clearance for its generic version of semaglutide

Participants using the Dexcom G7 saw an average 1.6% reduction in their blood sugar levels at 26 weeks, a 0.9% greater reduction than those who used self-monitoring

A large-scale study finds semaglutide may lower the risk of depression and anxiety, adding an unexpected mental health dimension to its known physical health benefits

Alembic Pharmaceuticals Ltd on Tuesday said it has received final approval from the US health regulator for its generic version of dapagliflozin tablets used to control blood sugar levels in people with type-2 diabetes. The approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of dapagliflozin tablets of strengths 5 mg and 10 mg, Alembic Pharmaceuticals Ltd said in a regulatory filing. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Farxiga Tablets, 5 mg and 10 mg, of AstraZeneca AB (AstraZeneca), it added. Alembic was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Dapagliflozin Tablets, 5 mg and 10 mg. With this approval, Alembic is eligible for 180 days of shared generic drug marketing exclusivity, the company said. Dapagliflozin tablet is indicated to reduce the risk of hospitalisation for heart failure in adults with ...

Findings show metformin acts on the brain at low doses, reshaping decades of understanding and pointing to more targeted approaches in diabetes treatment

World Obesity Day: Is weight loss after 60 always healthy? Doctors explain who benefits, when it can backfire, and why strength, mobility and nutrition may matter more than the scale

Researchers report the first successful reversal of type 2 diabetes using stem cells, restoring natural insulin production and offering hope beyond lifelong insulin dependence

A large global genetics study shows Type 2 diabetes is driven by complex, tissue-specific biology across organs and populations, challenging blood-focused research and treatment strategies

Changing lifestyles, nutritional gaps and untreated mental health issues are pushing chronic diseases into younger age groups across India

A new human heart study shows type 2 diabetes does not just raise cardiac risk but physically alters heart muscle, energy use and structure, helping explain why heart failure is so common in diabetes

Researchers analysing decades of data report that diabetes, especially type 2, is linked to impaired male fertility, driven largely by inflammatory processes in the body

Beyond crash diets and fads, doctors say diabetes remission is driven by realistic lifestyle changes, early action and consistency, not extreme workouts or quick fixes

From regulating appetite to improving blood sugar control, GLP-1 drugs like Ozempic are emerging as powerful metabolic tools at a time when India urgently needs better solutions

Ozempic debuts in India at ₹2,200 per week, offering a new treatment option for type 2 diabetes as demand grows for effective and easy-to-use metabolic health therapies

A new study shows how gut-produced metabolites influence insulin response and fat metabolism, opening the door to potential future treatments for obesity and type 2 diabetes

As diabetes rises to one in six Indians and Gen Z struggles across all wellness pillars, a new study highlights how stress, inactivity and sugar-heavy diets are reshaping the nation's health

Cipla- Eli Lilly deal: Tirzepatide is a prescription drug used for managing type 2 diabetes and aiding weight loss in adults who are obese or overweight.

Prediabetes may have no clear symptoms, but early detection and small lifestyle changes can help reverse the risk